Introduction to TACT
Kathryn Wagner, as Chair, is leading this exciting initiative with the support of the core committee, nominated extended committee members and the TREAT-NMD secretariat.
In order to oversee the work of TACT on a regular basis and to provide guidance on its structure and content, a ‘core’ group serves as a driver and common denominator of a broader membership.
Working closely with the Chair and core group are >70 additional international multidisciplinary experts, each with specific expertise in one or more of the areas of drug development. Such expertise include: discovery research, preclinical assessment of animal and cellular models, chemistry, preclinical pharmacology, formulation, toxicology, biostatistics, regulatory expertise in both the US and the EU, clinical care, clinical research, clinical development, clinical trial expertise, ethics, patient advocacy and funding of development programmes.
TACT is supported by the TREAT-NMD secretariat and importantly, patient organisation representation who help with the selection of projects, as part of the review panel, and in providing part funding for meeting costs. All members of TACT are required to sign a common confidentiality and disclosure agreement, binding for all of the information received from applicants, and conflict of interest statements are updated on a meeting-by-meeting basis.